Ertugliflozin decreases the insulin spike in non-insulin dysregulated standardbred horses following intra-articular triamcinolone administration
An anti-diabetes drug reduces harmful insulin spikes in horses with metabolic syndrome, reducing laminitis risk in veterinary patients.
A randomized crossover trial in 8 horses demonstrates that oral ertugliflozin significantly attenuates the post-steroid insulin spike, potentially reducing laminitis risk in horses with equine metabolic syndrome. This is veterinary translational research with no direct human clinical application in this study.
What the study was
- Study design
- Randomized blinded placebo-controlled crossover study (veterinary)
- Population
- Adult standardbred gelding horses (n=8); equine metabolic syndrome model
- Sample size
- 8
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Domestic Animal Endocrinology
Why it surfaced
Veterinary study only; SGLT2 inhibitor in equine model; no direct human clinical relevance; watchlist match peripheral.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.